Modified 2/1 Sunitinib Schedule May Be Safer in Renal Cell Carcinoma
Patients with metastatic renal cell carcinoma who transitioned to a modified 2/1 schedule of sunitinib experience an improved safety profile compared with that observed during the initial 4/2 schedule, a new study published online ahead of print in the ...
Cancer Therapy Advisor - Wed, 29 Jul 2015 08:33

A case of metastatic renal cell carcinoma and bile duct carcinoma treated with ...
UroToday - Wed, 29 Jul 2015 08:17



FDA Grants Breakthrough Designation to Lenvatinib for Renal Cell Carcinoma
The FDA has granted a breakthrough therapy designation to lenvatinib (Lenvima) as a potential treatment for patients with advanced renal cell carcinoma (RCC) who have received a VEGF-targeted therapy, according to a statement from Eisai, the company ...
OncLive - Tue, 28 Jul 2015 06:52

FDA Grants Breakthrough Therapy Designation to Eisai's Lenvatinib
Drug Discovery & Development - Tue, 28 Jul 2015 04:48



FDA Approves Sonidegib (Odomzo) for Basal Cell Carcinoma
The US Food and Drug Administration (FDA) has approved the once-a-day 200 mg oral therapy sonidegib (Odomzo, Novartis) for the treatment of locally advanced basal cell carcinoma, which accounts for approximately 80% of nonmelanoma skin cancers.
Medscape - Fri, 24 Jul 2015 11:26

FDA Approves Sonidegib for Basal Cell Carcinoma
OncLive - Fri, 24 Jul 2015 08:09

FDA Approves Drug for Basal Cell Carcinoma
MedPage Today - Fri, 24 Jul 2015 11:22

FDA Announces Recent Approval For New Basal Cell Carcinoma Treatment from ...
Pioneer News - Sat, 25 Jul 2015 07:37

FDA approves new treatment for most common form of advanced skin cancer
FDA.gov - Fri, 24 Jul 2015 08:45

Novel Drug to treat Advanced basal cell carcinoma gets go-ahead from FDA
NYC Today - Sat, 25 Jul 2015 09:07

New Skin Cancer Drug Approved by FDA
U.S. News & World Report - Fri, 24 Jul 2015 11:38



Letrozole May Provide More Benefit in Lobular Carcinoma than Ductal Carcinoma
Patients diagnosed with early-stage invasive ductal carcinoma (IDC) or classic invasive lobular carnoma (ILC) who were randomly assigned onto the Breast International Group (BIG) 1-98 trial and who had centrally reviewed pathology data were included ...
Cancer Therapy Advisor - Tue, 28 Jul 2015 08:10

Research and Markets: Adrenocortical Carcinoma (Adrenal Cortex Cancer ...
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Insights provides the in-depth analysis of the pipeline assets across the Adrenocortical Carcinoma (Adrenal Cortex Cancer). The main objective of this report to track competitor pipeline ...
Business Wire (press release) - Wed, 29 Jul 2015 10:26



Frequent, Actionable MET Gene Mutations Found in Pulmonary Sarcomatoid Carcinoma
Mutational events that lead to MET exon 14 skipping occur frequently and may be targetable events in patients with pulmonary sarcomatoid carcinoma (PSC), according to a recent study published online ahead of print in the Journal of Clinical Oncology.
Cancer Therapy Advisor - Tue, 28 Jul 2015 08:00

Lenvatinib Granted Breakthrough Therapy for Advanced or Metastatic Renal Cell ...
Eisai announced that the Food and Drug Administration (FDA) granted lenvatinib Breakthrough Therapy designation for use in patients with advanced or metastatic renal cell carcinoma (RCC) who were previously treated with a vascular endothelial growth ...
Monthly Prescribing Reference (registration) - Tue, 28 Jul 2015 08:22

FDA Approves Odomzo for Basal Cell Carcinoma
The FDA has approved sonidegib (Odomzo, Novartis) for treating patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, as well as patients who are not fit for surgery or radiation therapy. The ...
Pharmacy Practice News - Mon, 27 Jul 2015 12:52


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014